These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 8122286)
21. Optimizing scaleup yield for protein production: Computationally Optimized DNA Assembly (CODA) and Translation Engineering. Hatfield GW; Roth DA Biotechnol Annu Rev; 2007; 13():27-42. PubMed ID: 17875472 [TBL] [Abstract][Full Text] [Related]
22. Challenges and opportunities in biotechnology. Overby LR Prog Clin Biol Res; 1985; 182():425-43. PubMed ID: 2994109 [TBL] [Abstract][Full Text] [Related]
23. The locks and keys to industrial biotechnology. Wohlgemuth R N Biotechnol; 2009 Apr; 25(4):204-13. PubMed ID: 19429540 [TBL] [Abstract][Full Text] [Related]
27. The use of gene fusions to protein A and protein G in immunology and biotechnology. Ståhl S; Nygren PA Pathol Biol (Paris); 1997 Jan; 45(1):66-76. PubMed ID: 9097850 [TBL] [Abstract][Full Text] [Related]
28. Drug products of recombinant DNA technology. Black WJ Am J Hosp Pharm; 1989 Sep; 46(9):1834-44. PubMed ID: 2679063 [TBL] [Abstract][Full Text] [Related]
29. The rapid discovery of engineered antibodies. Wang M; He M IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332 [TBL] [Abstract][Full Text] [Related]
30. Biotechnology-a sustainable alternative for chemical industry. Gavrilescu M; Chisti Y Biotechnol Adv; 2005 Nov; 23(7-8):471-99. PubMed ID: 15919172 [TBL] [Abstract][Full Text] [Related]
31. The control of biological medicinal products produced by recombinant DNA technology. Griffiths E Dev Biol Stand; 1985; 59():155-9. PubMed ID: 4007273 [TBL] [Abstract][Full Text] [Related]
32. Use of molecular techniques in bioremediation. Płaza G; Ulfig K; Hazen TC; Brigmon RL Acta Microbiol Pol; 2001; 50(3-4):205-18. PubMed ID: 11930989 [TBL] [Abstract][Full Text] [Related]
33. Biosimilars: current status and future directions. Roger SD Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525 [TBL] [Abstract][Full Text] [Related]
34. Fish vaccine antigens produced or delivered by recombinant DNA technologies. Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855 [TBL] [Abstract][Full Text] [Related]
35. [Research on the development of common basic technologies for cancer research]. Soga K Gan No Rinsho; 1989 Jan; 35(2):127-31. PubMed ID: 2704118 [TBL] [Abstract][Full Text] [Related]
36. [Twenty years development of metabolic engineering--a review]. Zhang X Sheng Wu Gong Cheng Xue Bao; 2009 Sep; 25(9):1285-95. PubMed ID: 19938469 [TBL] [Abstract][Full Text] [Related]
37. Genetic and phenotypic markers and their relationship to product quality and consistency. Adamson SR; Charlebois TS Dev Biol Stand; 1994; 83():31-44. PubMed ID: 7883098 [TBL] [Abstract][Full Text] [Related]
38. Aggregates in monoclonal antibody manufacturing processes. Vázquez-Rey M; Lang DA Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193 [TBL] [Abstract][Full Text] [Related]
39. Monoclonal and recombinant antibodies, 30 years after .. Laffly E; Sodoyer R Hum Antibodies; 2005; 14(1-2):33-55. PubMed ID: 16424599 [TBL] [Abstract][Full Text] [Related]
40. Biopharmaceuticals derived from genetically modified plants. Goldstein DA; Thomas JA QJM; 2004 Nov; 97(11):705-16. PubMed ID: 15496527 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]